Jamie E Chaft1, Ibiayi Dagogo-Jack2, Fernando C Santini1, Juliana Eng1, Beow Y Yeap2, Benjamin Izar3, Emily Chin2, David R Jones4, Mark G Kris1, Alice T Shaw2, Justin F Gainor5. 1. Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, United States. 2. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, United States. 3. Dana Farber Cancer Institute, Boston, MA, United States. 4. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States. 5. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, United States. Electronic address: jgainor@partners.org.
Abstract
OBJECTIVES: Reports of the prognostic significance of ALK-rearrangement in resected non-small cell lung cancer (NSCLC) have been contradictory. We aimed to determine the prognosis of early-stage ALK-positive lung cancers relative to KRAS- and EGFR-mutant lung cancers. MATERIAL AND METHODS: We reviewed medical records of patients with resected NSCLC harboring an ALK rearrangement (n = 29) or a driver mutation in EGFR (n = 255) or KRAS (n = 480). Recurrence-free survival (RFS) was estimated for each genotype with the differences reported as a hazard ratio (HR). RESULTS: Among the 764 patients, 555 (73%), 101 (13%), and 108 (14%) had stage I, II, and III NSCLC, respectively. ALK-positive patients were distributed across all stages: 10 (34%) stage I, 6 (21%) stage II, and 13 (45%) stage III. Median RFS was not reached for EGFR-mutant patients, 24.3 months (95%CI 11.4-65.3) for ALK-positive patients, and 72.9 months (95%CI 59.7 to undefined) for KRAS-mutant patients. When adjusted for stage, ALK-positive NSCLC remained associated with worse RFS compared to EGFR-mutant (HR 1.8, 95%CI: 1.1-3.1), but not when compared to KRAS-mutant (HR 1.3, 95%CI: 0.8-2.1) NSCLC. CONCLUSIONS: In this large series of resected NSCLC, ALK rearrangements were associated with a trend toward inferior disease outcomes compared to other clinically relevant genomic subsets. These data support the need for clinical trials evaluating use of ALK inhibitors among ALK-positive patients with localized or locally-advanced disease.
OBJECTIVES: Reports of the prognostic significance of ALK-rearrangement in resected non-small cell lung cancer (NSCLC) have been contradictory. We aimed to determine the prognosis of early-stage ALK-positive lung cancers relative to KRAS- and EGFR-mutant lung cancers. MATERIAL AND METHODS: We reviewed medical records of patients with resected NSCLC harboring an ALK rearrangement (n = 29) or a driver mutation in EGFR (n = 255) or KRAS (n = 480). Recurrence-free survival (RFS) was estimated for each genotype with the differences reported as a hazard ratio (HR). RESULTS: Among the 764 patients, 555 (73%), 101 (13%), and 108 (14%) had stage I, II, and III NSCLC, respectively. ALK-positive patients were distributed across all stages: 10 (34%) stage I, 6 (21%) stage II, and 13 (45%) stage III. Median RFS was not reached for EGFR-mutant patients, 24.3 months (95%CI 11.4-65.3) for ALK-positive patients, and 72.9 months (95%CI 59.7 to undefined) for KRAS-mutant patients. When adjusted for stage, ALK-positive NSCLC remained associated with worse RFS compared to EGFR-mutant (HR 1.8, 95%CI: 1.1-3.1), but not when compared to KRAS-mutant (HR 1.3, 95%CI: 0.8-2.1) NSCLC. CONCLUSIONS: In this large series of resected NSCLC, ALK rearrangements were associated with a trend toward inferior disease outcomes compared to other clinically relevant genomic subsets. These data support the need for clinical trials evaluating use of ALK inhibitors among ALK-positive patients with localized or locally-advanced disease.
Authors: Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn Journal: JAMA Date: 2014-05-21 Impact factor: 56.272
Authors: Ping Yang; Kimary Kulig; Jennifer M Boland; Michele R Erickson-Johnson; Andre M Oliveira; Jason Wampfler; Aminah Jatoi; Claude Deschamps; Randolph Marks; Connie Fortner; Shawn Stoddard; Francis Nichols; Julian Molina; Marie-Christine Aubry; Hui Tang; Eunhee S Yi Journal: J Thorac Oncol Date: 2012-01 Impact factor: 15.609
Authors: Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate Journal: J Clin Oncol Date: 2009-08-10 Impact factor: 44.544
Authors: Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger Journal: J Mol Diagn Date: 2015-03-20 Impact factor: 5.568
Authors: Min Hwan Kim; Hyo Sup Shim; Dae Ryong Kang; Ji Ye Jung; Chang Young Lee; Dae Joon Kim; Jin Gu Lee; Mi Kyung Bae; Hye Ryun Kim; Sun Min Lim; Eun Young Kim; Ji Soo Park; Kyung Young Chung; Hyun-Jung Kim; Joo Hang Kim; Byoung Chul Cho Journal: Lung Cancer Date: 2014-01-14 Impact factor: 5.705
Authors: Ramaswamy Govindan; Sumithra J Mandrekar; David E Gerber; Geoffrey R Oxnard; Suzanne E Dahlberg; Jamie Chaft; Shakun Malik; Margaret Mooney; Jeffrey S Abrams; Pasi A Jänne; David R Gandara; Suresh S Ramalingam; Everett E Vokes Journal: Clin Cancer Res Date: 2015-12-15 Impact factor: 12.531
Authors: Fiona H Blackhall; Solange Peters; Lukas Bubendorf; Urania Dafni; Keith M Kerr; Henrik Hager; Alex Soltermann; Kenneth J O'Byrne; Christoph Dooms; Aleksandra Sejda; Javier Hernández-Losa; Antonio Marchetti; Spasenija Savic; Qiang Tan; Erik Thunnissen; Ernst-Jan M Speel; Richard Cheney; Daisuke Nonaka; Jeroen de Jong; Miguel Martorell; Igor Letovanec; Rafael Rosell; Rolf A Stahel Journal: J Clin Oncol Date: 2014-07-28 Impact factor: 44.544
Authors: Dora Dias-Santagata; Sara Akhavanfard; Serena S David; Kathy Vernovsky; Georgiana Kuhlmann; Susan L Boisvert; Hannah Stubbs; Ultan McDermott; Jeffrey Settleman; Eunice L Kwak; Jeffrey W Clark; Steven J Isakoff; Lecia V Sequist; Jeffrey A Engelman; Thomas J Lynch; Daniel A Haber; David N Louis; Leif W Ellisen; Darrell R Borger; A John Iafrate Journal: EMBO Mol Med Date: 2010-05 Impact factor: 12.137
Authors: Marco de Scordilli; Anna Michelotti; Elisa Bertoli; Elisa De Carlo; Alessandro Del Conte; Alessandra Bearz Journal: Int J Mol Sci Date: 2022-06-29 Impact factor: 6.208
Authors: Maria Walls; Gerard M Walls; Jacqueline A James; Kyle T Crawford; Hossam Abdulkhalek; Tom B Lynch; Aaron J Peace; Terry E McManus; O Rhun Evans Journal: BMC Pulm Med Date: 2020-08-06 Impact factor: 3.317